5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cabozantinib (XL184) at 40 mg in patients with metastatic castration resistant prostate cancer (mCRPC): Results of a phase 2 non-randomized expansion cohort (NRE)
    Meeting Abstract

    de Bono, J. S.; Smith, M. R.; Rathkopf, D.; Corn, P. G.; Mukherji, D.; Harzstark, A. L.; Sartor, O. A.; Smith, D. C.; Tunariu, N.; Sweeney, C.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • The analytical validation of prostate specific mRNA detection in whole blood by reverse transcription-polymerase chain reaction (RT-PCR) as a prognostic biomarker for patients with castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Danila, D.; Anand, A.; Heller, G.; Wan, M.; Zehnder, M.; Khanin, R.; Schultz, N.; Fleisher, M.; Lilja, H.; Scher, H. I.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • The impact of abiraterone acetate (AA) therapy on patient-reported pain and functional status in chemotherapy-naive patients with progressive, metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Basch, E.; Ryan, C. J.; Kheoh, T.; Fizazi, K.; Logothetis, C. J.; Rathkopf, D. E.; Smith, M. R.; Mainwaring, P. N.; Hao, Y.; Griffin, T.; more...
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Next-generation sequencing reveals genomic determinants of long-term response to mTOR inhibitors in patients with advanced RCC
    Meeting Abstract

    Voss, M. H.; Hakimi, A. A.; Brannon, A. R.; Scott, S.; Takeda, S.; Liu, H.; Chen, Y.; Motzer, R. J.; Berger, M. F.; Hsieh, J. J.
    BJU International (2012)

    Fulltext@MSK | Save
  • Tivozanib pharmacokinetic (PK)/pharmacodynamic (PD) analysis of blood pressure and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) in patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Nosov, D. A.; Motzer, R. J.; Loewy, J.; Hodge, L.; Esteves, B.; Berkenblit, A.; Yin, W.; Dykstra, K.; Hutson, T. E.; Cotreau, M. M.
    BJU International (2012)

    Fulltext@MSK | Save
  • Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial
    Meeting Abstract

    Motzer, R.; Nosov, D.; Eisen, T.; Bondarenko, I.; Lesovoy, V.; Lipatov, O.; Tomczak, P.; Lyulko, O.; Alyasova, A.; Harza, M.; more...
    BJU International (2012)

    Fulltext@MSK | Save
  • Tumor suppressor screens of 3p chromatin modulators link BAP1 mutations to poor clinical outcomes in clear cell renal cell carcinoma
    Meeting Abstract

    Hakimi, A. A.; Chen, Y. B.; Wren, J.; Ostrovnaya, I.; Gonen, M.; Abdel-Wahab, O.; Heguy, A.; Liu, H.; Takeda, S.; Tickoo, S. K.; more...
    BJU International (2012)

    Fulltext@MSK | Save
  • Detailed comparison of the safety of tivozanib versus sorafenib in patients with advanced/metastatic renal cell carcinoma (mRCC) from a Phase III trial
    Meeting Abstract

    Eisen, T.; Sternberg, C. N.; Tomczak, P.; Harza, M.; Jinga, V.; Esteves, B.; Motzer, R.
    BJU International (2012)

    Fulltext@MSK | Save
  • Open-label phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Agarwala, S. S.; Wang, J.; Ye, D.; Sallo, V.; Stergiopoulos, S. G.; Brechenmacher, T.; Motzer, R. J.
    BJU International (2012)

    Fulltext@MSK | Save
  • Disruption of Abi1/Hssh3bp1 expression induces prostatic intraepithelial neoplasia in the conditional Abi1/Hssh3bp1 KO mice
    Journal Article

    Xiong, X.; Chorzalska, A.; Dubielecka, P. M.; White, J. R.; Vedvyas, Y.; Hedvat, C. V.; Haimovitz-Friedman, A.; Koutcher, J. A.; Reimand, J.; Bader, G. D.; more...
    Oncogenesis (2012)

    Fulltext@MSK | Save